The Impact of Imatinib on Survival and Treatment Trends for Small Bowel and Colorectal Gastrointestinal Stromal Tumors

Hamda Almaazmi, Miloslawa Stem, Brian D. Lo, James P. Taylor, Sandy H. Fang, Bashar Safar, Jonathan E. Efron, Chady Atallah

Research output: Contribution to journalArticlepeer-review

3 Scopus citations


Background: The aim of this study is to assess treatment trends and overall survival (OS) in small bowel (SB) and colorectal (CR) gastrointestinal stromal tumors (GIST) with respect to the introduction of imatinib in 2008. Methods: Patients diagnosed with SB and CR GIST were identified from the National Cancer Database (2004–2015). The primary outcome was 5- and 10-year OS. Patients were stratified by tumor site, time period (before and after imatinib), and treatment type. OS was analyzed using Kaplan-Meier survival curves, log-rank test, and Cox proportional hazards models. Results: A total of 8441 cases were included (SB 81.66%; CR 18.34%). Radical resection was the most common treatment (SB 42.33%; CR 38.69%). The addition of chemotherapy to radical resection for SB GIST increased between the two time periods (31.76 to 40.43%; p < 0.001), and was associated with improved unadjusted and adjusted OS (2009–2015: adjusted HR [AHR] 0.73, 95% CI 0.59–0.89, p = 0.002). Patients with SB GIST had better 5- and 10-year OS compared with CR (SB 69.83% and 47.68%; CR 61.33% and 45.39%; p < 0.001), even after stratifying by treatment type and tumor size and adjusting for other factors (SB 5-year AHR 1.35, 95% CI 1.19–1.53; 10-year AHR 1.23, 95% CI 1.09–1.38; each p < 0.001). Conclusion: CR GIST are associated with lower OS than SB GIST. Radical resection is the most common treatment type for both sites. Chemotherapy with radical resection offers better OS in SB GIST, but not in CR GIST. Further studies are needed to assess the biology of CR GIST to explain the worse OS.

Original languageEnglish (US)
Pages (from-to)98-108
Number of pages11
JournalJournal of Gastrointestinal Surgery
Issue number1
StatePublished - Jan 1 2020


  • Chemotherapy
  • Colorectal
  • GIST
  • Gastrointestinal stromal tumor
  • Imatinib
  • Small bowel

ASJC Scopus subject areas

  • Surgery
  • Gastroenterology


Dive into the research topics of 'The Impact of Imatinib on Survival and Treatment Trends for Small Bowel and Colorectal Gastrointestinal Stromal Tumors'. Together they form a unique fingerprint.

Cite this